Header Logo

Connection

Alan Schneyer to Molecular Sequence Data

This is a "connection" page, showing publications Alan Schneyer has written about Molecular Sequence Data.
Connection Strength

0.229
  1. Saito S, Sidis Y, Mukherjee A, Xia Y, Schneyer A. Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3. Endocrinology. 2005 Dec; 146(12):5052-62.
    View in: PubMed
    Score: 0.048
  2. Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology. 2002 May; 143(5):1613-24.
    View in: PubMed
    Score: 0.038
  3. Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL. Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology. 2001 Aug; 142(8):3426-34.
    View in: PubMed
    Score: 0.036
  4. Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology. 1996 Feb; 137(2):486-94.
    View in: PubMed
    Score: 0.025
  5. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006 May; 38(5):531-9.
    View in: PubMed
    Score: 0.012
  6. Babitt JL, Zhang Y, Samad TA, Xia Y, Tang J, Campagna JA, Schneyer AL, Woolf CJ, Lin HY. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem. 2005 Aug 19; 280(33):29820-7.
    View in: PubMed
    Score: 0.012
  7. Sidis Y, Schneyer AL, Keutmann HT. Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology. 2005 Jan; 146(1):130-6.
    View in: PubMed
    Score: 0.011
  8. del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem. 2004 May 21; 279(21):22765-72.
    View in: PubMed
    Score: 0.011
  9. Keutmann HT, Schneyer AL, Sidis Y. The role of follistatin domains in follistatin biological action. Mol Endocrinol. 2004 Jan; 18(1):228-40.
    View in: PubMed
    Score: 0.011
  10. Sidis Y, Schneyer AL, Sluss PM, Johnson LN, Keutmann HT. Follistatin: essential role for the N-terminal domain in activin binding and neutralization. J Biol Chem. 2001 May 25; 276(21):17718-26.
    View in: PubMed
    Score: 0.009
  11. Urbanek M, Wu X, Vickery KR, Kao LC, Christenson LK, Schneyer A, Legro RS, Driscoll DA, Strauss JF, Dunaif A, Spielman RS. Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab. 2000 Dec; 85(12):4455-61.
    View in: PubMed
    Score: 0.009
  12. Wang Q, Keutmann HT, Schneyer AL, Sluss PM. Analysis of human follistatin structure: identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins. Endocrinology. 2000 Sep; 141(9):3183-93.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.